
Hereditary ovarian cancer
The resources below have been developed to support implementation of mainstreaming of the R207 Inherited ovarian cancer (without breast cancer cancer) panel now includes BRCA1/2, PALB2, MLH1, MHS2, MSH6, BRIP1, RAD51C and RAD51D through cancer services in Nottinghamshire, Lincolnshire and Derbyshire. We call this Mainstreaming Cancer Genetics (MCG).
These resources have been designed for use within our Trust and the district hospital which we serve. Any of the specialist nurses or clinicians involved in the care of patients with ovarian cancer can complete the training resources.
Please note that up to the 1/1/2023 we were only able to offer the R207 lite panel which didn’t include RAD51C, RAD51D and BRIP1.
If you have queries please contact: nuhnt.clinicalgenetics@nhs.net.
Steps for training
Steps for training
1. Email nuhnt.clinicalgenetics@nhs.net to arrange a time for face to face or virtual training.
2. Read the frequently asked questions before the face to face training: MCG-FAQ1 V3.doc [doc] 119KB
Useful documents
• Frequently asked questions booklet: MCG-FAQ1 V3.doc [doc] 119KB
• Protocol for the Nottingham gynae-oncology appointment: MCG P2 V6 Ovarian Notts.pptx [pptx] 119KB
• Family history questionnaire: FHQ.xls [xls] 37KB
• Record of discussion (consent) form for patients with ovarian cancer: MCG-OVARIAN ROD FORM 05.05.22.docx [docx] 35KB
• UK Cancer Genetics Group BRCA1 guidelines: UKCGG_BRCA1_guideline_FINALv2_31032023_A4_PDF.pdf [pdf] 208KB
• UK Cancer Genetics Group BRCA2 guidelines: UKCGG_BRCA2_guideline_FINALv2_31032023_A4_PDF.pdf [pdf] 209KB
• UK Cancer Genetics Group FAQ about BRCA guidelines: FAQ for Management Guidelines for BRCA1 and BRCA2 Germline Pathogenic Variant Carriers for Healthcare Professionals v2 31032023 (2).pdf [pdf] 254KB
• UK Cancer Genetics Group BRIP1 guidelines: BRIP1_FINAL_ v1_31032023_A4_PDF.pdf [pdf] 222KB
• UK Cancer Genetics Group PALB2 guidelines: PALB2 guidelines_FINAL_v1_ 31032023_A4_PDF.pdf [pdf] 232KB
• UK Cancer Genetics Group Management Guidelines for MLH1.pdf [pdf] 571KB
• UK Cancer Genetics Group Management Guidelines for MSH2.pdf [pdf] 571KB
• UK Cancer Genetics Group Management Guidelines for MSH6.pdf [pdf] 569KB
• UK Cancer Genetics Group Management Guidelines for PMS2.pdf [pdf] 637KB
• UK Cancer Genetics Group Management Guidelines for Lynch syndrome FAQ.pdf [pdf] 408KB
Information sheets for patients
•Information about R207 Ovarian panel testing: MCG IS6-R207- v3- Pt info ovarian cancer.doc [doc] 116KB
•A normal result: MCG-IS2-V5-Pt-info-normal-result-all genes.doc [doc] 62KB
•An unclassified variant: MCG-IS4-v4-Pt-info-VUS-all genes.docx [docx] 97KB
•A positive BRCA1/2 result: MCG IS3-v4-BRCA positive.doc [doc] 194KB
•A positive PALB2 result: MCG IS5-v4 Pt info-PALB2 positive.doc [doc] 154KB
•A positive Lynch (MLH1, MSH2, MSH6) result: MCG IS7-v1 Pt info-Lynch positive.doc [doc] 195KB
•A positive BRIP1 result: MCG IS12-v1 Pt info-BRIP1.doc [doc] 154KB
•A positive RAD51C/D result: MCG IS11-v1 Pt info-RAD51C-D.doc [doc] 154KB
Suggested template letters for patients
- Ovarian normal result template letter: MCG GRL1 Ov normal result updated 2023.doc [doc] 78KB
- Ovarian pathogenic variant template letter: MCG GRL2 Ov Pathogenic variant updated 2023.doc [doc] 81KB
- Ovarian variant of unknown significance template letter: MCG GRL3 Ov VUS updated 2023.doc [doc] 78KB